Aggreva 0,05 mg/ml Injection

Indication

Used for the prevention of thrombotic events in patients with acute coronary syndrome (ACS) and during percutaneous coronary interventions (PCI).

Dosage (summary)

Initial bolus of 0.4 mcg/kg/min for 30 minutes, followed by a continuous infusion of 0.1 mcg/kg/min.

Onset of Action / Duration

Onset of action is typically within 30 minutes, with effects lasting for several hours after discontinuation.

Special Populations

• Elderly patients
• Patients with renal impairment
• Patients with hepatic impairment

Pregnancy & Breastfeeding

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is advised when administering to nursing mothers.

Key Drug Interactions

• Increased risk of bleeding with anticoagulants such as warfarin and heparin.
• Caution with antiplatelet agents like aspirin and clopidogrel.

Contraindications

• Active bleeding or a history of bleeding disorders.
• Severe thrombocytopenia.
• Hypersensitivity to tirofiban or any component of the formulation.

Common side effects

• Bleeding complications.
• Thrombocytopenia.
• Nausea.
• Headache.
• Hypotension.

Counselling Points

• Inform patients about the signs of bleeding and when to seek medical attention.
• Advise patients to report any unusual bruising or bleeding.
• Discuss the importance of adhering to follow-up appointments and monitoring.